The FDA rejects its own safety center’s call for the strongest warning label on COVID-19 vaccines, even as new data links the shots to child deaths and heart inflammation.
By yourNEWS Media Newsroom
The Food and Drug Administration will not add “black box” warnings—the agency’s highest safety alert—to COVID-19 vaccines, FDA Commissioner Dr. Marty Makary announced on December 15.
“When it comes to the ‘black box’ warning, we have no plans to put that on the COVID vaccine,” Makary stated during an appearance on Bloomberg Television. Black box warnings are reserved for cases where adverse reactions are so severe that they must be considered when evaluating a drug’s risks and benefits, or when proper use can prevent serious harm.
The decision follows an FDA memorandum released in November, which revealed that at least 10 child deaths were linked to COVID-19 vaccination after reviewing autopsy reports. The agency has since expanded its investigation to include other age groups.
Regulators previously updated vaccine labels to warn about myocarditis, a form of heart inflammation most commonly observed in young males aged 12 to 24 after receiving Pfizer-BioNTech or Moderna vaccines. This risk was identified after the FDA first authorized COVID-19 vaccines in December 2020.
Makary confirmed that an FDA safety and epidemiology center had recommended a black box warning due to the myocarditis risk. However, he explained that Dr. Vinay Prasad, the agency’s top vaccine official, and other FDA leaders rejected the recommendation. “When you have those two doses three months apart, that’s when you see the side effects go way up, like myocarditis in young people,” Makary said. “Now that it’s annual, you may not see that same prevalence. So we don’t want to extrapolate findings to today if it’s not transferable.”
COVID-19 vaccines were initially recommended for nearly all Americans, but the Trump administration later narrowed their clearance, advising annual vaccination only after consultation with a healthcare professional. This guidance considers individual risk factors, such as obesity, which may increase the likelihood of severe COVID-19 outcomes.
Moderna and Pfizer continue to defend their vaccines, asserting that they protect people and maintain favorable safety profiles, a position supported by groups like the American Academy of Pediatrics, which counts both companies among its partners.
Despite these assurances, some experts and advocates have called for the removal of COVID-19 vaccines from the market, citing ongoing concerns about their safety and long-term effects. The FDA’s decision not to implement a black box warning has reignited debates over vaccine safety, regulatory transparency, and the balance between public health benefits and risks.
Original article
Comments